Skip to Content
Merck
CN

45720

Eserine salicylate salt

≥97.0% (N)

Synonym(s):

Physostigmine salicylate salt

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C15H21N3O2 · C7H6O3
CAS Number:
Molecular Weight:
413.47
EC Number:
200-343-8
UNSPSC Code:
12352005
PubChem Substance ID:
Beilstein/REAXYS Number:
3900576
MDL number:
Assay:
≥97.0% (N)
Form:
powder
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Eserine salicylate salt, ≥97.0% (N)

InChI key

HZOTZTANVBDFOF-PBCQUBLHSA-N

InChI

1S/C15H21N3O2.C7H6O3/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2;8-6-4-2-1-3-5(6)7(9)10/h5-6,9,13H,7-8H2,1-4H3,(H,16,19);1-4,8H,(H,9,10)/t13-,15+;/m1./s1

SMILES string

OC(=O)c1ccccc1O.CNC(=O)Oc2ccc3N(C)[C@H]4N(C)CC[C@@]4(C)c3c2

biological source

synthetic

assay

≥97.0% (N)

form

powder

optical activity

[α]20/D −77±2°, c = 1% in ethanol

mp

181-183 °C

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Acetylcholinesterase inhibitor that crosses the blood-brain barrier and forms a carbamylated enzyme complex with acetyl cholinesterase that degrades slowly.

pictograms

Skull and crossbones

signalword

Danger

Hazard Classifications

Acute Tox. 2 Inhalation - Acute Tox. 2 Oral

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

F Matschiner et al.
HNO, 49(12), 1026-1028 (2002-01-17)
Appearance of an anticholinergic syndrome after treatment with drugs in therapeutic dosages is seldom reported in the literature. Based on a case report, the development and course of an anticholinergic syndrome after treatment with dimenhydrinate are described. The drug was
F J Forno et al.
The Journal of the American Osteopathic Association, 98(9), 502-504 (1998-10-24)
Ingestion of jimsonweed can result in hallucinations. Despite this side effect, the differential diagnosis of jimsonweed toxicity can be difficult, in part, because routine drug screens do not detect this agent. Such a delay in diagnosis not only postpones treatment
A Bringmann
Neuroscience letters, 202(1-2), 13-16 (1995-12-29)
In previous experiments it was found that physostigmine application in unrestrained rats delayed the peak latency of the visual evoked potential (VEP). The present study was carried out to find the putative site that cholinergically mediates the latency delay of
H Jesionowska et al.
The Journal of reproductive medicine, 36(3), 167-169 (1991-03-01)
A subcutaneous injection of physostigmine was employed to treat paraplegic anejaculation. The sperm motility was greater than in previously reported studies in which electroejaculation techniques were used for seminal emission.
Noushin Bolourchian et al.
Acta pharmaceutica (Zagreb, Croatia), 59(3), 301-312 (2009-10-13)
This study is aimed to design and optimize a sublingual tablet formulation of physostigmine salicylate, an effective drug in Alzheimer's disease and nerve gas poisoning, by means of the D-optimal experimental design methodology. Polyvinyl pyrrolidone, lactose, starch 1500 and sodium

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service